![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Novartis and Vernalis in cancer deal; alliance ends
Executive Summary
The Novartis Institutes for Biomedical Research has licensed exclusive worldwide rights to Vernalis PLC's (oncology and neurology) Hsp90 cancer research program. The deal follows a six-month evaluation period entered into by the companies last year in which Novartis had the option to license rights to the project.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice